Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ACADIA Pharmaceuticals Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Adult patients, aged 18 years and above
2. A clinical diagnosis of major depressive disorder (MDD)
3. Is being treated with one of the following SSRI or SNRI antidepressants as monotherapy:
* Citalopram
* Escitalopram
* Paroxetine
* Fluoxetine
* Sertraline
* Duloxetine
* Venlafaxine
* Desvenlafaxine
* Venlafaxine XR
4. Has a history of inadequate response to antidepressant treatments
You may not be if
1. Patient has a psychotic disorder other than MDD
2. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program
3. Patient has a history or symptoms of long QT syndrome
Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
Clareo Health | Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
